Bank OZK grew its holdings in shares of McKesson Co. (NYSE:MCK – Free Report) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,958 shares of the company’s stock after purchasing an additional 80 shares during the quarter. Bank OZK’s holdings in McKesson were worth $1,832,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in MCK. International Assets Investment Management LLC lifted its stake in shares of McKesson by 1,044.5% during the 4th quarter. International Assets Investment Management LLC now owns 821,262 shares of the company’s stock worth $380,228,000 after purchasing an additional 749,504 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of McKesson by 16.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,148,794 shares of the company’s stock worth $2,238,953,000 after purchasing an additional 708,438 shares during the period. Morgan Stanley lifted its stake in shares of McKesson by 14.0% during the 3rd quarter. Morgan Stanley now owns 2,398,380 shares of the company’s stock worth $1,042,937,000 after purchasing an additional 294,832 shares during the period. Caisse DE Depot ET Placement DU Quebec raised its position in shares of McKesson by 92.1% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 567,941 shares of the company’s stock worth $246,969,000 after buying an additional 272,266 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of McKesson by 5,683.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 225,016 shares of the company’s stock worth $104,178,000 after buying an additional 221,125 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on MCK. UBS Group increased their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Barclays began coverage on McKesson in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $537.00 target price on the stock. Morgan Stanley increased their target price on McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a research report on Monday, April 15th. Leerink Partnrs reaffirmed an “outperform” rating on shares of McKesson in a research report on Monday, February 26th. Finally, SVB Leerink assumed coverage on McKesson in a research report on Monday, February 26th. They issued an “outperform” rating and a $600.00 target price on the stock. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, McKesson currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.50.
McKesson Stock Up 0.6 %
Shares of McKesson stock traded up $3.36 during trading hours on Friday, hitting $543.30. 654,669 shares of the company’s stock traded hands, compared to its average volume of 493,786. The stock has a 50 day simple moving average of $528.15 and a 200-day simple moving average of $489.48. The company has a market cap of $71.40 billion, a PE ratio of 24.62, a PEG ratio of 1.43 and a beta of 0.45. McKesson Co. has a twelve month low of $352.34 and a twelve month high of $544.81.
McKesson (NYSE:MCK – Get Free Report) last announced its earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, beating the consensus estimate of $7.05 by $0.69. The company had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The company’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm earned $6.90 earnings per share. As a group, equities research analysts predict that McKesson Co. will post 27.59 EPS for the current year.
McKesson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, May 31st. This represents a $2.48 dividend on an annualized basis and a yield of 0.46%. McKesson’s dividend payout ratio (DPR) is 11.24%.
Insider Buying and Selling
In related news, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the transaction, the chief executive officer now directly owns 43,445 shares in the company, valued at $22,789,074.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the transaction, the chief executive officer now owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Leann B. Smith sold 186 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the transaction, the executive vice president now directly owns 1,511 shares in the company, valued at approximately $749,456. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.
McKesson Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Stories
- Five stocks we like better than McKesson
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 4/22 – 4/26
- When to Sell a Stock for Profit or Loss
- 3 Stocks Leading the U.S. Agriculture Comeback
- Energy and Oil Stocks Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.